We simplify market access for medical devices

Our proven experts guide you through medical device CE certification. You gain hands-on support in regulatory affairs and quality management, ensuring regulatory compliance. Plus, as a Swiss Authorised Representative, we facilitate your access to the medical device market in Switzerland.

100+ customers trust Decomplix

One partner for your medical device compliance

Obtain CE mark with proven experts

Decomplix becomes your professional compliance partner. We guide you to your CE mark and ensure your compliant quality management. You get expert advice on how to overcome key regulatory hurdles on the way to getting your product to market.

More about our CE mark services

Swiss Authorised Representative

As your Swiss Authorised Representative (CH-REP), we ensure your market access in Switzerland. Our high level of compliance and regulatory knowledge was confirmed with a Swissmedic inspection with no non-conformities in April 2022.

More about our CH-REP service

Compliance for Swiss medical device importers

We offer consulting, training and ready-to-use templates for procedures, checklists and other tools for the compliant import of medical devices into Switzerland. Our proven experts tailor the processes together with you to your needs for fixed price.

More about our importers service

CE-certified medical device software

Transform your algorithm into a CE-certified medical device software in less than a year. Decomplix, with its partner platform Evidencio, can offer a fast, proven, de-risked solution.

More about our medical device software service

100+ medical device and in-vitro diagnostic companies of all shapes and sizes trust Decomplix — from startups to corporates, from Switzerland to all around the globe.

Read more about us

Regulatory Affairs News

16.01.2025

European Commission

Updated version of Notified Body’s Preliminary Assessment Review (PAR) form templates MDCG 2024-7 rev.1 (under the EU MDR) and MDCG 2024-8 rev.1 (under the IVDR), and their related annexes:

  • Removed section G4 (on the compliance strategy with Annex VII) due to redundancy in use.

 

MedTech Europe

EU HTA regulation and EU harmonised assessment for digital medical devices (including AI)

  • An overview of existing evaluation frameworks for Digital Medical Devices (DMDs)
  • Limitations of existing evaluation frameworks across Europe

 

MedTech Europe 2024 Regulatory Survey: key findings and insights

  • Summary slide
  • Key findings on Certification Timelines, Challenges, Cost and Innovation. 
09.01.2025

European Commission

Updated guidance document MDCG 2023-3 rev. 2, Q&A on vigilance under EU MDR & IVDR. Changes include:

  • Minor updates to adapt to the upcoming Eudamed VGL (vigilance) module.
  • Clarification on the timelines for feedback from competent authorities on the draft FSN, i.e. 48 hours, equivalent to 2 working days.

 

Swiss Federal Council

The English version of the revised Swiss Ordinance on In-vitro Diagnostics, SR 812.219 IvDO was published. It had entered into force on 2025-01-01.

03.01.2025

Swissmedic

New version of Information sheet on Economic Operators (rev. 6.0) published, Changes include:

  • Removing the requirements of CH-REP labelling for IVDs CE-marked under the IVDR and not intended for self-testing, in alignment with the revised IvDO.
  • Updated flowchart and requirements for “legacy” IVDs.

New version of Information sheet on Procurement of Medical Devices in Healthcare Institutions (rev. 5.2) published. Changes include:

  • Minor amendments due to revision of IvDO.
  • Additional updates of topics that have evolved since the last version (e.g. swissdamed).

 

swissdamed 

  • The second module “Devices” will go live in several phases: after the first release in 2025, it will be possible to register certain devices, specifically “Regulation Devices” (i.e. those CE-marked under the EU MDR and IVDR), which will have to be uploaded using XML files in the EUDAMED format. Subsequent releases will complete the Devices module.
  • From 1 July 2026 and by the end of the transitional period on 31 December 2026, all devices, systems and procedure packs being placed on the Swiss market will have to have been registered in swissdamed.

 

Swiss Parliament

TPA revision, in force 2025-01-01:

  • New Article 33a, Art. 35 1bis, Art. 36 2bis (concerning prohibition of payment of blood donation)
  • Some wording modifications
16.01.2025

European Commission

Updated version of Notified Body’s Preliminary Assessment Review (PAR) form templates MDCG 2024-7 rev.1 (under the EU MDR) and MDCG 2024-8 rev.1 (under the IVDR), and their related annexes:

  • Removed section G4 (on the compliance strategy with Annex VII) due to redundancy in use.

 

MedTech Europe

EU HTA regulation and EU harmonised assessment for digital medical devices (including AI)

  • An overview of existing evaluation frameworks for Digital Medical Devices (DMDs)
  • Limitations of existing evaluation frameworks across Europe

 

MedTech Europe 2024 Regulatory Survey: key findings and insights

  • Summary slide
  • Key findings on Certification Timelines, Challenges, Cost and Innovation. 
09.01.2025

European Commission

Updated guidance document MDCG 2023-3 rev. 2, Q&A on vigilance under EU MDR & IVDR. Changes include:

  • Minor updates to adapt to the upcoming Eudamed VGL (vigilance) module.
  • Clarification on the timelines for feedback from competent authorities on the draft FSN, i.e. 48 hours, equivalent to 2 working days.

 

Swiss Federal Council

The English version of the revised Swiss Ordinance on In-vitro Diagnostics, SR 812.219 IvDO was published. It had entered into force on 2025-01-01.

Latest from our blog